Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim and Eli Lilly have announced FDA approval of Jentadueto (linagliptin/metformin hydrochloride) tablet, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.
Subscribe to our email newsletter
The newly approved drug provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control their blood sugar.
Jentadueto is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate, the Eli Lilly said.
At the maximum dose, Jentadueto demonstrated placebo-corrected reductions in hemoglobin A(1c) (HbA(1c) or A1C) levels of up to 1.7% (+0.1% for placebo and -1.6% for JJentadueto ).
Jentadueto can be used alone or in combination with a sulfonylurea, a commonly prescribed medication for type 2 diabetes.
Linagliptin (5mg, once-daily) is marketed as Tradjenta (linagliptin) tablets in the US.